3 Tiny Stocks Dodging the AI Bubble That Nobody's Talking About

Look, if your entire portfolio is just the Magnificent Seven doing the robot, you might want to read this. A recent Felix and Friends (Goat Academy) video on retirement prep made a sharp point: the two biggest risks right now are inflation eroding cash and overexposure to AI-driven equities that may already be overextended. The antidote? Assets less correlated with the AI hype cycle. So we did the digging, and found three genuinely obscure names that most retail investors have never googled, let alone bought.

$HCSG (Healthcare Services Group) is a Bensalem, PA-based company that provides housekeeping, laundry, linen, and dietary services to long-term care facilities, think nursing homes and assisted living centers. It has a market cap under $400M, zero AI hype attached to it, and a business model that is about as recession-resistant as it gets. The catalyst here is demographic: the U.S. 65-plus population is growing fast, and long-term care facilities are expanding to meet demand. Revenue has been under pressure recently, but margins are stabilizing and insider buying has quietly ticked up. Not glamorous. Potentially very smart.

$CECO (CECO Environmental Corp) does industrial air quality and fluid handling solutions for heavy industries like oil refining, cement, and chemical plants. Market cap sits around $600M. Nobody talks about this one at cocktail parties, which is exactly why it's interesting. The catalyst is a growing global push for industrial emissions compliance, and CECO is a picks-and-shovels play on that regulatory wave. Backlog has been growing for two consecutive quarters, and the stock trades at a reasonable multiple relative to peers. The bear case: execution risk on larger contracts and customer concentration in cyclical industries.

$RCUS (Arcus Biosciences) is a clinical-stage biotech focused on cancer immunotherapy, specifically targeting pathways that complement existing checkpoint inhibitors. Market cap is roughly $700M, down sharply from its 2021 peak, which means the bad news is largely priced in. The bull case: a partnership with Gilead Sciences provides non-dilutive funding and de-risked development. The bear case: it is still pre-revenue and biotech timelines are, famously, a suggestion. Upcoming data readouts from its lead programs are the catalysts to watch.

None of these are guaranteed winners. But in a market where everyone is crowded into the same ten names, the real alpha might be hiding in companies that fix nursing home laundry, clean industrial air, and quietly fight cancer. Sometimes boring is the new brilliant.